GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Small and Large Bowel/DGBI and Carbohydrate intolerance

DGBI and Carbohydrate intolerance

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated August 1, 2025

Quick Answer

**Disorders of Gut-Brain Interaction (DGBI) and Carbohydrate Intolerance:** **Overview of DGBI:** Disorders of Gut-Brain Interaction (DGBI) encompass a group of conditions characterized by abnormal communication between the gut and the brain. These disorders include conditions such as irritable bowel syndrome (IBS), functional dyspepsia, and functional constipation, among others.


**Disorders of Gut-Brain Interaction (DGBI) and Carbohydrate Intolerance:**

**Overview of DGBI:**

Disorders of Gut-Brain Interaction (DGBI) encompass a group of conditions characterized by abnormal communication between the gut and the brain. These disorders include conditions such as irritable bowel syndrome (IBS), functional dyspepsia, and functional constipation, among others. DGBI are not caused by structural abnormalities or diseases but rather by dysfunction in the gut-brain axis, leading to symptoms like abdominal pain, bloating, diarrhea, constipation, and altered bowel habits.

**Carbohydrate Intolerance in DGBI:**

Carbohydrate intolerance is a condition where the body has difficulty digesting certain types of carbohydrates, such as lactose (milk sugar) and fructose (fruit sugar). In a French study of 301 adults with DGBI, carbohydrate intolerance was found to be highly prevalent:

  • **Prevalence:** More than half (59%) of the participants had carbohydrate intolerance, involving lactose, fructose, or both. Additionally, 44% showed evidence of carbohydrate malabsorption on breath testing.
  • **Breakdown of Intolerance:**
  • 47 patients were intolerant to lactose only.
  • 54 patients were intolerant to fructose only.
  • 77 patients were intolerant to both lactose and fructose.

**Who Is Most Affected?**

  • **Gender:** Women were more likely to have carbohydrate intolerance compared to men.
  • **Multiple DGBIs:** Patients with multiple DGBI conditions were also more likely to experience carbohydrate intolerance.

**Clinical Impact:**

Carbohydrate intolerance in DGBI patients was associated with worse clinical outcomes:

  • **Worsened IBS Symptoms:** Patients with carbohydrate intolerance experienced more severe IBS symptoms compared to those without intolerance.
  • **Somatic Complaints:** These individuals reported more somatic complaints, which are physical symptoms not explained by underlying organic disease (e.g., fatigue, headaches, muscle pain).
  • **Lower Quality of Life:** Carbohydrate intolerance negatively impacted patients' overall quality of life.

**Key Findings:**

  • **Lactose Maldigestion:** Lactose maldigestion was strongly linked to carbohydrate intolerance and correlated with the severity of somatic symptoms.
  • **Fructose Malabsorption:** Fructose malabsorption alone was not significantly associated with worse symptoms or somatic complaints.

**Implications for Management:**

Carbohydrate intolerance is common in DGBI and contributes to the severity of symptoms. Identifying and addressing carbohydrate intolerance, particularly lactose-related intolerance, may help guide personalized treatment strategies. For example:

  • **Dietary Adjustments:** Eliminating or reducing problematic carbohydrates (e.g., lactose or fructose) from the diet may alleviate symptoms.
  • **Improved Quality of Life:** Targeted dietary interventions can potentially improve the quality of life for DGBI patients.

**Conclusion:**

Carbohydrate intolerance plays a significant role in exacerbating symptoms and reducing the quality of life in individuals with DGBI. Understanding the specific type of carbohydrate intolerance (lactose, fructose, or both) and tailoring management strategies accordingly could lead to better outcomes for these patients.

Related Q&A

Anal High-Grade Squamous Intraepithelial Lesions (HSIL): BJS | March 2026

Introduction: Anal squamous cell carcinoma is an increasingly common but largely preventable cancer. Most cases arise from persistent high-risk human papillomavirus (HPV) infection, progressing through high-grade squamous intraepithelial lesions (HSIL). This comprehensive review summarizes the...

Post-Infection DGBI (PI-DGBI): Gut | July 2026

Introduction: Acute infectious gastroenteritis can trigger persistent gastrointestinal symptoms long after the infection has resolved, leading to post-infection disorders of gut-brain interaction (PI-DGBI). This global Rome Foundation study evaluated the prevalence, risk factors, and clinical...

FMT in IBS: Gastroenterology | July 2026

Introduction: Gut microbiota alterations have been implicated in the pathogenesis of irritable bowel syndrome (IBS), making fecal microbiota transplantation (FMT) a promising therapeutic strategy. However, clinical trials have reported conflicting results. This updated meta-analysis evaluated...

Laparoscopic vs Open Adhesiolysis for Bowel Obstruction: JAMA Surgery | June 2026

Introduction: Laparoscopic adhesiolysis offers several short-term advantages over open surgery for adhesive small bowel obstruction (ASBO). However, its long-term impact on recurrence, quality of life, and incisional hernia remains uncertain. The LASSO trial provides the...

DPP-4 Inhibition Targets the Gut–Brain Axis in Parkinson's Disease: Gut | July 2026

Introduction: Growing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This study investigated whether sitagliptin, a widely used DPP-4 inhibitor for...

Bedside Ultrasound Outperforms Abdominal X-Ray in Neonatal Necrotizing Enterocolitis: Frontiers in Pediatrics | July 2026

Introduction: Necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal emergencies in neonates. Early identification of infants requiring surgical intervention is critical but remains challenging. This study compared bedside abdominal ultrasonography (US) with abdominal...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer